Updates

** Shares of generic drugmaker Viatris VTRS.O fall as much as 22% to over a year low of $8.77

** Stock last down 14% at $9.67 in afternoon trade

** Company forecast 2025 revenue to be between $13.5 billion and $14 billion, below analysts' estimate of $14.27 billion — LSEG

** Expects 2025 adj profit between $2.12/share and $2.26/share, compared with estimates of $2.59/share

** VTRS says it estimates FDA action will negatively impact its 2025 total revenues by about $500 million and adjusted core earnings by roughly $385 million

** Last year, FDA has restricted imports from Viatris' Indore facility in India due to regulatory violations

** VTRS also reports fouth-quarter adj profit of 54 cents/share, below analysts' estimate of 57 cents/share

** Posts quarterly sales of $3.52 billion, below analysts' est of $3.61 billion

** VTRS gained 8.6% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com))